Trichostatin a stabilizes the expression of pluripotent genes in human mesenchymal stem cells during ex vivo expansion

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Han, Bing ^a   Li, Jing ^a,b   Li, Zhilong ^b   Guo, Ling ^b   Wang, Shan ^b   Liu, Peishu ^a   Wu, Yaojiong ^b  

^a SHANDONG UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; TRICHOSTATIN A;

ACETYLATION; CELL ADHESION; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM;

ACETYLATION; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MESENCHYMAL STROMAL CELLS;

EID: 84894240842     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081781     Document Type: Article

References (23)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147. doi:10.1126/science.284.5411.143. PubMed: 10102814.
2. Prockop DJ (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71-74. doi:10.1126/science.276.5309.71. PubMed: 9082988.
3. Wu Y, Zhao RC, Tredget EE (2010) Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells 28: 905-915. PubMed: 20474078.
4. Williams AR, Hare JM (2011) Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 109: 923-940. doi:10.1161/CIRCRESAHA.111.243147. PubMed: 21960725.
5. Salem HK, Thiemermann C (2010) Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28: 585-596. PubMed: 19967788.
6. Mizuno H, Tobita M, Uysal AC (2012) Concise review: Adipose-derived stem cells as a novel tool for future regenerative medicine. Stem Cells 30: 804-810. doi:10.1002/stem.1076. PubMed: 22415904.
7. Romanov YA, Svintsitskaya VA, Smirnov VN (2003) Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate MSC-like cells from umbilical cord. Stem Cells 21: 105-110. doi:10.1634/stemcells.21-1-105. PubMed: 12529557.
8. Fukuchi Y, Nakajima H, Sugiyama D, Hirose I et al. (2004) Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 22: 649-658. doi:10.1634/stemcells.22-5-649. PubMed: 15342929.
9. Wagner W, Horn P, Castoldi M, Diehlmann A et al. (2008) Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLOS ONE 3: e2213. doi:10.1371/journal.pone.0002213. PubMed: 18493317.
10. Silva J, Smith A (2008) Capturing pluripotency. Cell 132: 532-536. doi:10.1016/j.cell.2008.02.006. PubMed: 18295569.
11. Han J, Mistriotis P, Lei P, Wang D et al. (2012) Nanog reverses the effects of organismal aging on mesenchymal stem cell proliferation and myogenic differentiation potential. Stem Cells 30: 2746-2759. doi:10.1002/stem.1223. PubMed: 22949105.
12. Yannarelli G, Pacienza N, Cuniberti L, Medin J et al. (2013) Brief report: The potential role of epigenetics on multipotent cell differentiation capacity of mesenchymal stromal cells. Stem Cells 31: 215-220. doi:10.1002/stem.1262. PubMed: 23097343.
13. Li Z, Liu C, Xie Z, Song P et al. (2011) Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation. PLOS ONE 6: e20526. doi:10.1371/journal.pone.0020526. PubMed: 21694780.
14. Philippe B, Luc S, Valérie PB, Jérôme R, et al. (2010) Culture and use of mesenchymal stromal cells in phase I and II clinical trials. Stem Cells Int 2010:503593
15. Wu Y, Chen L, Scott PG, Tredget EE (2007) Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25: 2648-2659. doi:10.1634/stemcells.2007-0226. PubMed: 17615264.
16. Lee OK, Kuo TK, Chen WM, Lee KD et al. (2004) Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 103: 1669-1675. doi:10.1182/blood-2003-05-1670. PubMed: 14576065.
17. Agalioti T, Chen G, Thanos D (2002) Deciphering the transcriptional histone acetylation code for a human gene. Cell 111: 381-392. doi:10.1016/S0092-8674(02)01077-2. PubMed: 12419248.
18. Lomvardas S, Thanos D (2001) Nucleosome sliding via TBP DNA binding in vivo. Cell 106: 685-696. doi:10.1016/S0092-8674(01)00490-1. PubMed: 11572775.
19. Vigushin DM, Ali S, Pace PE, Mirsaidi N et al. (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976. PubMed: 11309348.
20. Marsoni S, Damia G, Camboni G (2008) A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 3: 164-171. doi:10.4161/epi.3.3.6253. PubMed: 18487953.
21. Vanhaecke T, Papeleu P, Elaut G, Rogiers V (2004) Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 11: 1629-1643. doi:10.2174/0929867043365099. PubMed: 15180568.
22. Tan J, Huang H, Huang W, Li L et al. (2008) The genomic landscapes of histone H3-Lys9 modifications of gene promoter regions and expression profiles in human bone marrow mesenchymal stem cells. J Genet Genomics 35: 585-593. doi:10.1016/S1673-8527(08)60079-X. PubMed: 18937915.
23. Noer A, Lindeman LC, Collas P (2009) Histone H3 modifications associated with differentiation and long-term culture of mesenchymal adipose stem cells. Stem Cells Dev 18: 725-736. doi:10.1089/scd.2008.0189. PubMed: 18771397.